7.78 USD
▲+0.21+3.60%
2026-08-03
市值
$472.99M
市盈率
—
EPS
-3.22
股息率
—
52 周区间
2.80 – 13.67
成交量
563.65K
Beta
1.94
目标价
30.40
52W 低 2.8052W 高 13.67
价格走势
公司简介
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreemen...